

Tumour	Sequence and indel variants tested in these genes
Biliary adenocarcinoma	<i>BRAF, ERBB2, FGFR1, FGFR2, FGFR3, IDH1, KRAS, RET</i>
Breast carcinoma	<i>AKT1, BRAF, ERBB2, ESR1, PIK3CA, PTEN</i>
Colorectal, gastric, and oesophageal adenocarcinoma	<i>BRAF, ERBB2, KRAS, NRAS, PIK3CA, PTEN, MAP2K1, TP53</i>
Endometrial and ovarian carcinoma	<i>AKT1, BRAF, ERBB2, KRAS, TP53</i>
Gastrointestinal stromal tumour	<i>BRAF, KIT, PDGFRA</i>
Glioma	<i>ARAF, BRAF, CDK4, CTNNB1, EGFR, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, IDH1, IDH2, PDGFRA, PIK3CA, TERT, TP53</i>
Histiocytic tumour	<i>ARAF, BRAF, KRAS, MAP2K1, MAP2K2, NRAS, RAF1</i>
Melanoma	<i>BRAF, KIT, KRAS, NRAS, TERT</i>
Meningioma	<i>AKT1, BRAF, CDKN2A, PIK3CA, SMO, TERT</i>
Non-small cell lung carcinoma (NSCLC)	<i>BRAF, EGFR, ERBB2, KRAS, MET, TP53</i>
Salivary gland tumour	<i>AR, BRAF, ERBB2, FGFR1, FGFR2, FGFR3, RET</i>
Thyroid carcinoma	<i>ALK, BRAF, KRAS, NRAS, RET, TERT</i>
Urothelial carcinoma	<i>BRAF, FGFR1, FGFR2, FGFR3, HRAS, MTOR, TERT</i>

Table 1 : Oncomine Precision Assay Gene panels v.3.01
September 2026